Erratum: Real-world evidence of long-term survival and healthcare resource use in patients with hepatic encephalopathy receiving rifaximin-α treatment: a retrospective observational extension study with long-term follow-up (IMPRESS II)

This erratum addresses corrections to the original study on the long-term survival and healthcare resource use in patients with hepatic encephalopathy treated with rifaximin-α. The authors aimed to provide real-world evidence regarding the effectiveness of this treatment over an extended follow-up period. The corrections ensure the accuracy and reliability of the findings presented in the original publication.